Tentarix Biotherapeutics has filed a notice of an exempt offering of securities to raise $34,999,997.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Tentarix Biotherapeutics is raising $34,999,997.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Paul Grayson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Tentarix Biotherapeutics
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology. On an unprecedented scale, we are leading a fundamental change in the methods of discovery and engineering of multi-specific biologics. At Tentarix Biotherapeutics we are bringing powerful biology selectively to cell types that drive therapeutic benefit with multifunctional biologics that are manufacturable.
To learn more about Tentarix Biotherapeutics, visit http://www.tentarix.com/
Contact:
Paul Grayson, President and Chief Executive Officer
858-587-4815
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.